Beam Therapeutics Inc.
NasdaqGS:BEAM Stok Raporu
Beam Therapeutics Geçmiş Kazanç Performansı
Geçmiş kriter kontrolleri 0/6 Beam Therapeutics şirketinin kazançları yıllık ortalama -5% oranında azalırken, Biotechs sektörünün kazançları yıllık 19.3% oranında artan oldu. Gelirler yıllık ortalama 74.4% oranında artan oldu.
Anahtar bilgiler Biotechs Sektör Büyümesi 17.0% Gelir büyüme oranı 74.4% Özkaynak getirisi -18.1% Net Marj -41.1% Son Kazanç Güncellemesi 30 Sep 2024
Yakın geçmiş performans güncellemeleri
Third quarter 2024 earnings: EPS misses analyst expectations Nov 06
Second quarter 2024 earnings: EPS in line with expectations, revenues disappoint Aug 07
First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind May 07
Full year 2023 earnings: EPS and revenues exceed analyst expectations Feb 28
Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind Nov 10
Second quarter 2023 earnings: EPS and revenues exceed analyst expectations Aug 08
Tüm güncellemeleri göster
Beam Therapeutics: Additional BEAM-101 And ESCAPE Tech Data At ASH 2024 Makes This A Watch Nov 07
Third quarter 2024 earnings: EPS misses analyst expectations Nov 06
Insufficient Growth At Beam Therapeutics Inc. (NASDAQ:BEAM) Hampers Share Price Oct 28
President notifies of intention to sell stock Oct 17
CEO & Director notifies of intention to sell stock Oct 02
Beam Therapeutics: Still Holding Fast To Generous Valuation, Still Not A Buy Sep 29
We're Not Worried About Beam Therapeutics' (NASDAQ:BEAM) Cash Burn Sep 04
Second quarter 2024 earnings: EPS in line with expectations, revenues disappoint Aug 07 Beam Therapeutics Inc. Announces Resignation of Terry-Ann Burrell as Chief Financial Officer, Effective August 9, 2024 Jul 15
Beam Therapeutics Inc.'s (NASDAQ:BEAM) Prospects Need A Boost To Lift Shares Jul 12
Beam Therapeutics: Slow Developmental Progress, But Promising Potential Jul 01
CEO & Director notifies of intention to sell stock Jun 30
Beam Therapeutics Inc. Announces First Patient Dosed in the Phase 1/2 Study of BEAM-302 in Alpha-1 Antitrypsin Deficiency Jun 26
Consensus revenue estimates decrease by 21%, EPS upgraded May 14
We're Not Worried About Beam Therapeutics' (NASDAQ:BEAM) Cash Burn May 13
First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind May 07
Beam Therapeutics: A 'Hold' Amid High Valuation And Uncertain Revenue Prospects Apr 24
Beam Therapeutics Inc., Annual General Meeting, Jun 05, 2024 Apr 21
Lacklustre Performance Is Driving Beam Therapeutics Inc.'s (NASDAQ:BEAM) Low P/S Apr 07
CEO & Director notifies of intention to sell stock Apr 01
Beam Therapeutics Inc. Announces Clearance of Clinical Trial Authorisation Application for BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency Mar 26
Consensus revenue estimates fall by 11% Mar 05
Beam Therapeutics Inc. (NASDAQ:BEAM) Consensus Forecasts Have Become A Little Darker Since Its Latest Report Mar 01
Things Look Grim For Beam Therapeutics Inc. (NASDAQ:BEAM) After Today's Downgrade Feb 29
Full year 2023 earnings: EPS and revenues exceed analyst expectations Feb 28
Beam Therapeutics: Cool Tech, But At A Way Inflated Price For Now Feb 08
CEO & Director notifies of intention to sell stock Feb 02
Beam Therapeutics Inc. Highlights Progress Across Base Editing Portfolio and Outlines 2024 Anticipated Milestones Jan 08
Price target decreased by 8.0% to US$48.85 Dec 17
Beam Therapeutics Inc. Appoints Christi Shaw to Its Board of Directors Dec 14
Price target decreased by 8.8% to US$49.62 Dec 08
Senior VP notifies of intention to sell stock Nov 24
New minor risk - Share price stability Nov 15
Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind Nov 10
This Just In: Analysts Are Boosting Their Beam Therapeutics Inc. (NASDAQ:BEAM) Outlook for This Year Nov 01
Consensus revenue estimates increase by 25% Nov 01
Price target decreased by 17% to US$53.50 Oct 20
Beam, Inc. Announces Plans to Advance Clinical Trials and Programs Oct 20
Beam Therapeutics Inc. Presents Preclinical Data Highlighting Utility of Beam-302 to Correct an Alpha-1 Antitrypsin Deficiency Disease-Causing Mutation Sep 08
Second quarter 2023 earnings: EPS and revenues exceed analyst expectations Aug 08
President notifies of intention to sell stock Jul 24
We're Hopeful That Beam Therapeutics (NASDAQ:BEAM) Will Use Its Cash Wisely Jul 23
Consensus revenue estimates increase by 37%, EPS downgraded May 17
First quarter 2023 earnings: EPS in line with analyst expectations despite revenue beat May 11
Here's Why We're Not At All Concerned With Beam Therapeutics' (NASDAQ:BEAM) Cash Burn Situation Apr 08
CEO & Director exercised options to buy US$424k worth of stock. Apr 02
Price target decreased by 8.3% to US$69.53 Mar 22
Consensus revenue estimates increase by 17% Mar 07
Full year 2022 earnings released: US$3.72 loss per share (vs US$5.77 loss in FY 2021) Mar 01
CFO & Treasurer recently sold US$330k worth of stock Jan 22
President & Chief Scientific Officer exercised options and sold US$2.0m worth of stock Jan 09
President & Chief Scientific Officer notifies of intention to sell stock Dec 16
Beam Therapeutics Inc. Presents First In Vivo Proof of Concept Preclinical Data on Multiplex Base Edited ESCAPE Platform for Non-Genotoxic Conditioning Regimen for Patients with Sickle Cell Disease Ahead of Autologous Transplant Dec 13
Price target decreased to US$80.08 Nov 16
Beam Therapeutics Enrolls First Patient in Beacon Clinical Trial of Beam-101 Base Editing Therapy Candidate for the Treatment of Sickle Cell Disease Nov 15
Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind Nov 08
Industry Analysts Just Made A Massive Upgrade To Their Beam Therapeutics Inc. (NASDAQ:BEAM) Revenue Forecasts Nov 08
CEO & Director notifies of intention to sell stock Nov 05
Beam Therapeutics Inc. Presents First in Vivo Data Demonstrating Potential of Multiplex Base Editing Approach to Target Disease Drivers of Chronic Hepatitis B Infection Sep 20
Beam Therapeutics: Now Is Not The Right Time To Own Sep 15
Consensus forecasts updated Aug 16
Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind Aug 10
Beam Therapeutics Inc. Appoints John Lo as Chief Commercial Officer Aug 10
Beam Therapeutics GAAP EPS of -$1.02 misses by $0.05, revenue of $16.65M beats by $7.21M Aug 09
CEO & Director notifies of intention to sell stock Aug 05
Beam Therapeutics Inc. Announces FDA Clinical Hold on BEAM-201 IND Application Aug 02
Beam drops 19% as FDA issues clinical hold on blood cancer candidate Aug 01
Revisiting Beam Therapeutics Among Collaborative Catalysts Jul 10
Price target decreased to US$90.58 Jun 17
Consensus revenue estimates fall by 37% May 16
Price target decreased to US$102 May 11
First quarter 2022 earnings: EPS and revenues miss analyst expectations May 10 Beam Therapeutics Inc. Announces Executive Changes May 10
Newsflash: Beam Therapeutics Inc. (NASDAQ:BEAM) Analysts Have Been Trimming Their Revenue Forecasts May 10
Beam Therapeutics to Present New Preclinical Data from Base Editing Pipeline at ASGCT 25th Annual Meeting May 03
CEO & Director notifies of intention to sell stock May 02
Price target decreased to US$116 Apr 28
Beam Therapeutics Inc., Annual General Meeting, Jun 08, 2022 Apr 23
Beam Therapeutics Worth Watching Because Of Pfizer Interest? Apr 21
Beam Therapeutics: Getting More And More Interesting Apr 10
CEO & Director recently sold US$370k worth of stock Apr 08
Beam Therapeutics Inc. (NASDAQ:BEAM) Analysts Are Cutting Their Estimates: Here's What You Need To Know Mar 03
Some Beam Therapeutics Inc. (NASDAQ:BEAM) Analysts Just Made A Major Cut To Next Year's Estimates Mar 02
Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat Mar 01
Consensus forecasts updated Mar 01
CEO & Director notifies of intention to sell stock Feb 04
Pfizer's Partnership With Beam Therapeutics About Becoming Global Leader In mRNA/Gene Therapy Jan 19
Consensus revenue estimates increase by 74% Jan 13
Beam Therapeutics Reports Progress Across Ex Vivo and in Vivo Pipeline of Base Editing Therapeutics Jan 10
Beam Therapeutics: An Early Company In A Promising Field Dec 27
President & Chief Scientific Officer notifies of intention to sell stock Dec 24
Beam Therapeutics: Recent Selling Pressure Leaves Behind A CRISPR Buying Opportunity Dec 20
Consensus forecasts updated Dec 11
Third quarter 2021 earnings released: US$0.42 loss per share (vs US$0.69 loss in 3Q 2020) Nov 10
CEO & Director notifies of intention to sell stock Oct 11
Beam Therapeutics: This Technology Should Be Part Of Every Investor's Portfolio Oct 01
Beam Therapeutics nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.
Kazanç ve Gelir Geçmişi NasdaqGS:BEAM Gelir, gider ve kazançlar (USD Millions ) Tarih Gelir Kazançlar G+A Giderleri Ar-Ge Giderleri 30 Sep 24 350 -144 126 0 30 Jun 24 353 -143 125 0 31 Mar 24 361 -135 120 0 31 Dec 23 378 -133 117 0 30 Sep 23 82 -314 96 0 30 Jun 23 80 -327 93 0 31 Mar 23 77 -316 92 0 31 Dec 22 61 -289 88 0 30 Sep 22 92 -315 83 0 30 Jun 22 77 -234 77 0 31 Mar 22 60 -238 66 0 31 Dec 21 52 -371 57 0 30 Sep 21 1 -401 48 0 30 Jun 21 0 -408 40 0 31 Mar 21 0 -366 33 0 31 Dec 20 0 -196 30 0 30 Sep 20 0 -132 27 0 30 Jun 20 0 -119 25 0 31 Mar 20 0 -106 23 0 31 Dec 19 0 -91 21 0 30 Sep 19 0 -86 18 0 30 Jun 19 0 -134 15 0 31 Mar 19 0 -124 13 0 31 Dec 18 0 -117 12 0
Kaliteli Kazançlar: BEAM şu anda kârlı değil.
Büyüyen Kar Marjı: BEAM şu anda kârlı değil.
Serbest Nakit Akışı ve Kazanç Analizi
Geçmiş Kazanç Büyüme Analizi
Kazanç Eğilimi: BEAM kârlı değildir ve zararlar son 5 yılda yılda 5% oranında artmıştır.
Büyüme Hızlandırma: BEAM 'un son bir yıldaki kazanç büyümesinin 5 yıllık ortalamasıyla karşılaştırılması mümkün değil çünkü şu anda kârlı değil
Kazançlar vs. Sektör: BEAM kârlı olmadığından, geçmiş yıl kazanç büyümesinin Biotechs sektörüyle ( 16.6% ) karşılaştırılması zorlaşıyor.
Özkaynak Getirisi
Yüksek ROE: BEAM hissesi şu anda kârlı olmadığından negatif Özsermaye Getirisi 'ne ( -18.15% ) sahiptir.
Kullanılan Sermaye Getirisi
Geçmişte güçlü performans gösteren şirketleri keşfedin Simply Wall St™ Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":true,"variant":{"name":"control","enabled":true,"feature_enabled":true,"featureEnabled":true},"flagsReady":true,"flagsError":null}
